Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Selinexor in Combination With R-CHOP for Untreated TP53-mutated DLBCL
NCT06517511Phase 2Recruiting
- Sponsor
- Sun Yat-sen University
- Start
- Aug 2024
- Primary completion
- Jan 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of selinexor in diffuse large B-cell lymphoma (DLBCL), sponsored by Sun Yat-sen University. Started Aug 2024; status: recruiting.
02
Drugs
selinexor
03
Conditions
diffuse large B-cell lymphoma (DLBCL)
Beyond the preview
Go deeper on NCT06517511.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06517511.